Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Mar 6;36(4):459–468. doi: 10.1093/carcin/bgv017

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2015. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — Fra-1 plays a critical role in IL-6 induced EMT and cell mobility. (A) Morphology of HT-29 cells with siRNAs against Fra-1 or scrambled control and stimulated with 50ng/mL of IL-6 for 72h. Scale bar, 20 μm. (B) Western blots of 72h IL-6 treated HT-29 cells receiving the indicated siRNAs using specific antibodies. (C) Western blots of HT-29 cells transfected with Fra-1 expression vector or empty vector and indicated siRNAs and incubated with IL-6 for 72h afterwards. (D) Left panels: images from scratch assays with HT-29 cells transfected with indicated siRNAs. Scale bar, 200 μm. Right panel: percentage wound closure 24h after stimulation with IL-6. *P < 0.05. (E) Left panels: representative images of HT-29 tumor cells penetrating the Matrigel in invasion assays. Scale bar, 100 μm. Right panel: numbers of invasive cells transfected with the indicated siRNAs and exposed to IL-6 for 48h. *P < 0.05.